ONYX PHARMA - Carfilzomib Approval - Now or Later?
Future growth remains tied to the Approval of Carfilzomib (PhIIb, next-generation proteasome inhibitor, Relapsed and Refractory Multiple Myeloma - R/R MM). Delay could limit the potential of Carfilzomib, as generic Takeda’s Velcade (L, MM – first and second-line, MCL) might become available from 2017 coupled with probable approval of Celgene’s Pomalidimide (PhII, RR MM). There are two registration PhIII trials underway – ASPIRE (International) and FOCUS (EU), and interim data from these studies are expected to be out only in 1H13. Moreover, Bayer settled its litigation with ONXX... For more details, please read our report, released on Nov. 8, 2011 on “Onyx Pharma - Carfilzomib Approval – Now or Later?”
COMPANIES MENTIONED
ONYX
ONYX
